Thursday, August 16, 2018 8:03:55 AM
Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,860,778 shares of its common stock, at a purchase price per share of $1.15, for gross proceeds of approximately $10.19 million, in a registered direct offering priced at-the-market. Additionally, Pain Therapeutics has also agreed to issue to the investors unregistered warrants to purchase up to 8,860,778 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $1.11 million. The closing of the offering is expected to occur on or about August 17, 2018, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The warrants have an exercise price of $1.25 per share of common stock, will be exercisable immediately and will expire two and one-half years from the issuance date.
Pain Therapeutics intends to use the net proceeds from this offering for drug development and general corporate purposes and for other working capital and general corporate purposes.
New York Yankees and Duke Basketball
Recent SAVA News
- Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ • GlobeNewswire Inc. • 05/01/2024 01:10:00 PM
- Redemption Date Announced for Warrants • GlobeNewswire Inc. • 04/15/2024 01:20:00 PM
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials • GlobeNewswire Inc. • 03/25/2024 01:13:00 PM
- Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference • GlobeNewswire Inc. • 03/04/2024 02:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:01:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:22:12 PM
- Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates • GlobeNewswire Inc. • 02/28/2024 02:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 02:20:27 PM
- No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months • GlobeNewswire Inc. • 02/07/2024 02:08:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 09:00:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:23:45 PM
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders • GlobeNewswire Inc. • 01/05/2024 02:12:00 PM
- Form CERT - Certification by an exchange approving securities for listing • Edgar (US Regulatory) • 01/03/2024 09:24:43 PM
- Form 424B2 - Prospectus [Rule 424(b)(2)] • Edgar (US Regulatory) • 01/03/2024 09:22:52 PM
- Form 8-A12B - Registration of securities [Section 12(b)] • Edgar (US Regulatory) • 01/03/2024 09:18:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 02:10:10 PM
- Form 8-A12G - Registration of securities [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 02:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:19:07 PM
- Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders • GlobeNewswire Inc. • 12/12/2023 02:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:18:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:06:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:57:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:55:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM